title: Dyshidrotic eczema associated with the use of IVIg.
abstract: Intravenous immunoglobulin (IVIg) treatment is highly effective for autoimmune diseases including myasthenia gravis. Recovery is observed at approximately. 75% of myasthenia gravis patients through IVIg treatment. As a result of many clinical studies, the recommended dose is determined as 0.4 g/kg for 5 days (maximum total dose at 2 g/kg body weight). If an additional immunomodulatory treatment is not administered, IVIg maintenance treatment is needed mostly. However, some side effects may inhibit long-term treatment. For this reason, it is important to know the effect profile well and when the treatment should be discontinued. A female myasthenia gravis patient case is presented here, where dyshidrotic eczema has occurred after the second dose of  intravenous Ig medication and whose treatment is despite further IVIg therapy.
authors: Department of Neurology, Sakarya University Faculty of Medicine, Sakarya, Turkey. dilcankotan@yahoo.com
authors: Dilcan
authors: D
authors: Kotan
authors: Teoman
authors: T
authors: Erdem
authors: Bilgehan Atilgan
authors: BA
authors: Acar
authors: Ayhan
authors: A
authors: Boluk
mesh_terms: D000328:Adult; D003937:Diagnosis, Differential; D011146:Eczema, Dyshidrotic / Q000139:chemically induced* / Q000175:diagnosis; D005260:Female; D006801:Humans; D007116:Immunization, Passive / Q000009:adverse effects*; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000009:adverse effects*; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects; D009157:Myasthenia Gravis / Q000188:drug therapy
chemical_list: D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors